• Je něco špatně v tomto záznamu ?

Anti-apoptotic MCL1 Protein Represents Critical Survival Molecule for Most Burkitt Lymphomas and BCL2-negative Diffuse Large B-cell Lymphomas

M. Klanova, D. Kazantsev, E. Pokorna, T. Zikmund, J. Karolova, M. Behounek, N. Renesova, D. Sovilj, CD. Kelemen, K. Helman, R. Jaksa, O. Havranek, L. Andera, M. Trneny, P. Klener

. 2022 ; 21 (1) : 89-99. [pub] 20211102

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22011547

The pro-survival MCL1 protein is overexpressed in many cancers, including B-cell non-Hodgkin lymphomas (B-NHL). S63845 is a highly specific inhibitor of MCL1. We analyzed mechanisms of sensitivity/resistance to S63845 in preclinical models of diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma. Annexin V-based cytotoxic assays, Western blot analysis, protein co-immunoprecipitation, and cell clones with manipulated expression of BCL2 family proteins were used to analyze mechanisms of sensitivity to S63845. Experimental in vivo therapy with S63845 and/or venetoclax was performed using patient-derived xenografts (PDX) of treatment-refractory B-NHL. A subset of DLBCL and majority of Burkitt lymphoma cell lines were sensitive to S63845. The level of BCL2 protein expression was the major determinant of resistance to S63845: BCL2 serves as a buffer for pro-apoptotic proteins released from MCL1 upon exposure to S63845. While BCL2-negative lymphomas were effectively eliminated by single-agent S63845, its combination with venetoclax was synthetically lethal in BCL2-positive PDX models. Concerning MCL1, both, the level of MCL1 protein expression, and its occupational status represent key factors mediating sensitivity to S63845. In contrast to MCL1-BIM/BAK1 complexes that prime lymphoma cells for S63845-mediated apoptosis, MCL1-NOXA complexes are associated with S63845 resistance. In conclusion, MCL1 represents a critical survival molecule for most Burkitt lymphomas and a subset of BCL2-negative DLBCLs. The level of BCL2 and MCL1 expression and occupational status of MCL1 belong to the key modulators of sensitivity/resistance to S63845. Co-treatment with venetoclax can overcome BCL2-mediated resistance to S63845, and enhance efficacy of MCL1 inhibitors in BCL2-positive aggressive B-NHL.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22011547
003      
CZ-PrNML
005      
20220506130323.0
007      
ta
008      
220425s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1158/1535-7163.MCT-21-0511 $2 doi
035    __
$a (PubMed)34728569
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Klanova, Magdalena $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic $u First Department of Medicine-Department of Hematology, Charles University General Hospital, Prague, Czech Republic
245    10
$a Anti-apoptotic MCL1 Protein Represents Critical Survival Molecule for Most Burkitt Lymphomas and BCL2-negative Diffuse Large B-cell Lymphomas / $c M. Klanova, D. Kazantsev, E. Pokorna, T. Zikmund, J. Karolova, M. Behounek, N. Renesova, D. Sovilj, CD. Kelemen, K. Helman, R. Jaksa, O. Havranek, L. Andera, M. Trneny, P. Klener
520    9_
$a The pro-survival MCL1 protein is overexpressed in many cancers, including B-cell non-Hodgkin lymphomas (B-NHL). S63845 is a highly specific inhibitor of MCL1. We analyzed mechanisms of sensitivity/resistance to S63845 in preclinical models of diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma. Annexin V-based cytotoxic assays, Western blot analysis, protein co-immunoprecipitation, and cell clones with manipulated expression of BCL2 family proteins were used to analyze mechanisms of sensitivity to S63845. Experimental in vivo therapy with S63845 and/or venetoclax was performed using patient-derived xenografts (PDX) of treatment-refractory B-NHL. A subset of DLBCL and majority of Burkitt lymphoma cell lines were sensitive to S63845. The level of BCL2 protein expression was the major determinant of resistance to S63845: BCL2 serves as a buffer for pro-apoptotic proteins released from MCL1 upon exposure to S63845. While BCL2-negative lymphomas were effectively eliminated by single-agent S63845, its combination with venetoclax was synthetically lethal in BCL2-positive PDX models. Concerning MCL1, both, the level of MCL1 protein expression, and its occupational status represent key factors mediating sensitivity to S63845. In contrast to MCL1-BIM/BAK1 complexes that prime lymphoma cells for S63845-mediated apoptosis, MCL1-NOXA complexes are associated with S63845 resistance. In conclusion, MCL1 represents a critical survival molecule for most Burkitt lymphomas and a subset of BCL2-negative DLBCLs. The level of BCL2 and MCL1 expression and occupational status of MCL1 belong to the key modulators of sensitivity/resistance to S63845. Co-treatment with venetoclax can overcome BCL2-mediated resistance to S63845, and enhance efficacy of MCL1 inhibitors in BCL2-positive aggressive B-NHL.
650    _2
$a apoptóza $7 D017209
650    _2
$a Burkittův lymfom $x genetika $x mortalita $7 D002051
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a lidé $7 D006801
650    _2
$a difúzní velkobuněčný B-lymfom $x genetika $x mortalita $7 D016403
650    _2
$a protein MCL-1 $x metabolismus $7 D064549
650    _2
$a protoonkogenní proteiny c-bcl-2 $x metabolismus $7 D019253
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kazantsev, Dmitry $u BIOCEV, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Pokorna, Eva $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Zikmund, Tomas $u BIOCEV, First Faculty of Medicine, Charles University, Prague, Czech Republic $u Institute of Epigenetics and Stem cells, Helmholtz Centre Munich, Germany $1 https://orcid.org/0000000324523749
700    1_
$a Karolova, Jana $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic $u First Department of Medicine-Department of Hematology, Charles University General Hospital, Prague, Czech Republic $1 https://orcid.org/0000000338286000
700    1_
$a Behounek, Matej $u BIOCEV, First Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000260786653
700    1_
$a Renesova, Nicol $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Sovilj, Dana $u Institute of Biotechnology CAS/BIOCEV, Vestec, Czech Republic
700    1_
$a Kelemen, Cristina D $u Institute of Biotechnology CAS/BIOCEV, Vestec, Czech Republic
700    1_
$a Helman, Karel $u Prague University of Economics and Business, Prague, Czech Republic $1 https://orcid.org/0000000171418074 $7 xx0260953
700    1_
$a Jaksa, Radek $u Institute of Pathology, Charles University General Hospital, Prague, Czech Republic $1 https://orcid.org/0000000339104707
700    1_
$a Havranek, Ondrej $u First Department of Medicine-Department of Hematology, Charles University General Hospital, Prague, Czech Republic $u BIOCEV, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Andera, Ladislav $u Institute of Biotechnology CAS/BIOCEV, Vestec, Czech Republic $u Institute of Molecular Genetics CAS, Prague, Czech Republic
700    1_
$a Trneny, Marek $u First Department of Medicine-Department of Hematology, Charles University General Hospital, Prague, Czech Republic
700    1_
$a Klener, Pavel $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic. pavel.klener2@vfn.cz $u First Department of Medicine-Department of Hematology, Charles University General Hospital, Prague, Czech Republic $1 https://orcid.org/0000000177869378 $7 xx0105452
773    0_
$w MED00006616 $t Molecular cancer therapeutics $x 1538-8514 $g Roč. 21, č. 1 (2022), s. 89-99
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34728569 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130315 $b ABA008
999    __
$a ok $b bmc $g 1789253 $s 1162745
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 21 $c 1 $d 89-99 $e 20211102 $i 1538-8514 $m Molecular cancer therapeutics $n Mol Cancer Ther $x MED00006616
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Možnosti archivace